Business Wire

FL-AMGTA

24.4.2024 14:00:35 CEST | Business Wire | Press release

Share
AMGTA Releases Research on Sustainability of Powder and Wire Additive Feedstock

The Additive Manufacturer Green Trade Association (“AMGTA”) a global advocacy group focused on promoting sustainable additive manufacturing (“AM”) industry practices, announced today the preliminary results of a research project titled “Specific Energy of Metal AM Feedstock: A Comparison.” The study, commissioned by the AMGTA and conducted by Syntec Associates, a research consultancy, in partnership with Divergent Technologies, a complete modular digital factory for complex structures, evaluated three key metal AM feedstock processing approaches—gas atomization, mechanical milling (specifically ball milling), and wire drawing—to determine specific energy requirements for producing feedstock materials. The research findings highlighted that, from an energy perspective, helium gas atomization is the most sustainable method used for gas atomization for metallic powder production of commonly used alloys, followed by argon and then nitrogen. Specific energy consumption for atomization also critically depends on process parameters and alloy chemistry. Additionally, research showed that mechanical milling, when appropriate for use in powder production in additive manufacturing, exhibits a significant reduction in specific energy consumption when compared to gas atomization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416215703/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Photo courtesy of Carpenter Additive

“When preparing life cycle assessments on industrial rate processing of our alloys, I found wide variation in the literature on AM process and powder atomization energy consumption,” said Michael Kenworthy, Chief Technology Officer at Divergent Technologies and AMGTA Board Director. “This research established a transparent set of process assumptions and models from which to understand the key process levers and evaluate system trade studies that inform future sustainability enhancements.”

Key takeaways from this study include:

  • Helium Gas Atomization is Best for Powder Atomization: Research indicates that, from an energy perspective, helium gas atomization stands out as the most sustainable gas atomization method, showing a significant reduction in specific energy consumption compared to argon and nitrogen for commonly used alloys.
  • Argon Atomized Powder is Better than Nitrogen: For those seeking an alternative to helium, argon-atomized powder is revealed to be a notable option, energy savings when compared to nitrogen-atomized powder.
  • Mechanical Milling Outperforms Gas Atomization: Mechanical milling, particularly ball milling, demonstrates a significant reduction in specific energy consumption compared to gas atomization for metal AM powder production.
  • Industry Guidance for Sustainable Choices: This research highlights the importance of selecting manufacturing methods with the lowest specific energy consumption per kilogram to enhance overall sustainability when producing feedstock materials used in additive manufacturing.

“A primary goal of the AMGTA is to educate the consumer on the most sustainable methods of production within the additive supply chain. This important piece of research provides guidance on which methods of gas atomization require the least amount of specific energy per kilogram,” said Brian R. Neff, AMGTA’s Board Chair. “At the same time, it indicates to the market that mechanical production methods of powder feedstock, such as ball milling, are themselves an order of magnitude better than gas atomization from an energy perspective.”

Gas atomization, deemed a promising technology for producing stock powders for additive manufacturing, was a focal point of the study. The research revealed that gas atomization using helium as the atomization gas resulted in the least total specific energy consumption compared to argon (13% better on average) and nitrogen (28% better on average). Additionally, argon-atomized powder was found to reduce energy requirements by 12% when compared to nitrogen-atomized powder for the alloys studied (SS316L, Al5083, and IN718).

The study also highlights the efficiency of mechanical powder production, particularly ball milling, which showed approximately a 90% improvement in specific energy consumption compared to gas atomization for the range of process conditions studied. Further research is recommended to determine the applied impact within specific product categories of using helium-atomized powder and/or ball milled powder.

“This research aligns with the AMGTA commitment to better understand sustainable manufacturing practices leveraging additive technologies,” said Sherri Monroe, the AMGTA’s Executive Director. “These findings highlight key considerations for manufacturers seeking environmentally friendly feedstock production methods. To advance sustainability in additive manufacturing, research is vital in order to make informed decisions.”

Highlights from the study can be found on the AMGTA’s website. The AMGTA says it expects to publish additional independent research throughout 2024. Additional information on this study and others conducted by the AMGTA can be found on the AMGTA website, www.AMGTA.org.

About the AMGTA

The AMGTA was launched in 2019 to better understand and promote the environmental benefits of additive manufacturing across the global economy. AMGTA members represent the entirety of the manufacturing spectrum - from design and raw materials to end products and users - focused on innovating better, more sustainable, and financially advantageous products through best additive practices. For more information, please visit www.amgta.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416215703/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye